Table 1.
Number of cases and ROR (95% CI) of each NSAID-induced lower gastrointestinal tract injury adverse event reported in FAERS.
| LGTI | Other AE | LGTI (%) | ROR | 95% CI | |
|---|---|---|---|---|---|
| [I] | |||||
| Loxoprofen (+) | 269 | 10,232 | 2.56 | 4.23 | 3.75–4.78 |
| Loxoprofen (−) | 37,288 | 5,998,541 | 0.68 | ||
| [III] | |||||
| Diclofenac (+) | 907 | 31,476 | 2.80 | 4.70 | 4.40–5.02 |
| Diclofenac (−) | 36,650 | 5,977,297 | 0.61 | ||
| [II] | |||||
| Loxoprofen | |||||
| Rebamipide (+) | 76 | 2613 | 2.83 | 1.15 | 0.88–1.51 |
| Rebamipide (−) | 192 | 7620 | 2.46 | ||
| [IV] | |||||
| Diclofenac | |||||
| Rebamipide (+) | 20 | 548 | 3.52 | 1.28 | 0.82–2.01 |
| Rebamipide (−) | 880 | 30,935 | 2.76 | ||
Lower gastrointestinal tract injury of single-drug NSAIDs [I], [III]. Lower gastrointestinal tract injury with concomitant use of rebamipide and NSAIDs [II], [IV].
LGTI lower gastrointestinal tract injury, AE adverse event.